Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 933
- 主要终点
- Intraocular Pressure (IOP) at Baseline
研究概览
简要总结
This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting. Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after baseline, as per normal clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of POAG or OHT
- •Prescribed Lumigan® 0.01%
排除标准
- 未提供
研究组 & 干预措施
All participants
Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) eye drops at a dose and frequency as determined by the physician.
干预措施: Bimatoprost 0.01% ophthalmic solution (Drug)
结局指标
主要结局
Intraocular Pressure (IOP) at Baseline
时间窗: Baseline
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eye at Baseline.
Intraocular Pressure (IOP) at Week 12
时间窗: Week 12
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left eye and the right eye at Week 12. The lower the IOP values the greater the improvement.
次要结局
- Physician Assessment of Treatment Tolerability Using a 4-Point Scale(12 weeks)
- Physician Reported Reasons for Treatment Discontinuation(12 weeks)
- Number of Patients Continuing Treatment After 12 Weeks(12 weeks)
- Patient Assessment of Treatment Tolerability Using a 4-Point Scale(12 weeks)